News for STERIS plc (STE)

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Steris PLC (STE) has recently been in the spotlight, drawing interest from investors and financial analysts due to its robust financial stance. With shares curr

On March 3, 2025, Isomedix Operations, Inc., a subsidiary of STERIS plc (STE), announced that it has entered into binding confidential term sheets and settlem

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.

Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Strengths: Market leadership in sterilization services and a robust product portfolio in infection prevention.Weaknesses: Potential financial impact from ongoi

Total Revenue Growth: 6% reported growth, 6% constant currency organic growth.Gross Margin: Increased by 90 basis points to 44.6%.EBIT Margin: Decreased by 10

Feb 06, 2025 / 02:00PM GMTOperator Good day and welcome to the Steris PLC third quarter 2025 conference call. (Operator Instructions) Please note this event is

STERIS plc (NYSE:STE) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ETCompany ParticipantsJulie Winter – Investor RelationsMike Tokich – Senior...

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Steris (STE) delivered earnings and revenue surprises of 0% and 0.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[533463]**

Boston Scientific, Hologic, BioTechne, STERIS and Align are included in this Analyst Blog.

Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

**media[526713]**

Steris (STE) announces $0.57/share quarterly dividend, consistent with previous, with a forward yield of 1.03%.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

STE expects bioprocessing revenues to grow in the second half of fiscal 2025.